Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron in Type 2 Diabetes with Inadequate Glycemic Control on Insulin Glargine
NCT06109311Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of orforglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Hemoglobin A1c at 40 weeks. Started Nov 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06109311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109311.